AnaptysBio (ANAB) CLO sells 2,983 shares to cover RSU tax

Rhea-AI Filing Summary

AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related share sale. On January 3, 2026, 7,287 restricted stock units converted into an equal number of AnaptysBio common shares at an exercise price of $0, reflecting previously granted equity that vested. The RSUs vest 25% per year starting on January 3, 2025, as long as he continues providing services to the company.

On January 5, 2026, Loumeau sold 2,983 common shares at $43.26 per share. According to the disclosure, this sale was a “sell to cover” transaction used solely to satisfy tax withholding obligations tied to the RSU vesting and was not a discretionary trade. After these transactions, he held 13,251 AnaptysBio common shares directly and 14,575 RSUs representing additional potential shares upon future vesting.

Insider Trade Summary

Net Seller: 2,983 shares ($129,045)

Net Sell 3 txns

Insider LOUMEAU ERIC J

Role CHIEF LEGAL OFFICER

Sold 2,983 shs ($129K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,983	$43.26	$129K
Exercise	Restricted Stock Unit	7,287	$0.00	--
Exercise	Common Stock	7,287	$0.00	--

Holdings After Transaction: Common Stock — 13,251 shares (Direct); Restricted Stock Unit — 14,575 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOUMEAU ERIC J

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/03/2026		M		7,287	A	(1)	16,234	D
Common Stock	01/05/2026		S(2)		2,983	D	$43.26	13,251	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/03/2026		M			7,287	(3)	(3)	Common Stock	7,287	$0	14,575	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AnaptysBio (ANAB) report for Eric Loumeau?

The filing shows that Eric Loumeau, AnaptysBio’s chief legal officer, had 7,287 restricted stock units convert into common stock on January 3, 2026 and then sold 2,983 common shares on January 5, 2026.

How many AnaptysBio shares did Eric Loumeau sell and at what price?

Eric Loumeau sold 2,983 shares of AnaptysBio common stock at a price of $43.26 per share on January 5, 2026.

Why did the AnaptysBio chief legal officer sell 2,983 shares?

The filing states the sale was made to cover tax withholding obligations related to the vesting and settlement of RSUs through a “sell to cover” transaction and was not a discretionary trade by Eric Loumeau.

What RSU activity did Eric Loumeau report at AnaptysBio?

On January 3, 2026, 7,287 restricted stock units vested and converted into 7,287 AnaptysBio common shares at an exercise price of $0, reflecting previously granted equity awards.

How do Eric Loumeau’s AnaptysBio RSUs vest over time?

The RSUs vest as to 25% of the total award each year, starting on January 3, 2025, and continue annually until fully vested, subject to his continued service with AnaptysBio on each vesting date.

How many AnaptysBio shares and RSUs does Eric Loumeau hold after these transactions?

Following the reported transactions, Eric Loumeau directly held 13,251 common shares of AnaptysBio and 14,575 restricted stock units, which represent additional potential shares upon future vesting.